 - To evaluate the clinical benefit rate complete response, partial response, and stable disease for 14 weeks in patients with metastatic nasopharyngeal carcinoma treated with autologous dendritic cells DC transduced with AD5F35 expressing LMP-1 and LMP-2 when administered in combination with celecoxib. 